| 04-16-2012 10:33 PM CET - Science & Education |
|
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Press release from: Proteros biostructures GmbH
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.
Dr. Klaus Hinterding, Proteros CSO, stated: “We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai’s research activities using our unique technology platform.
About Proteros:
Proteros is a privately held company, which provides services and proprietary technologies to support knowledge-driven drug discovery programs. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ capabilities with its unique technology platform and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan.
About Eisai:
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com/.
Proteros biostructures GmbH
Dr. Thomas Waldmann
Bunsenstrasse 7a
82152 Martinsried
Germany
Phone: +49 89 7007 61 – 0
E-Mail: business@proteros.com
Internet: www.proteros.com
This release was published on openPR.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.
Dr. Klaus Hinterding, Proteros CSO, stated: “We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai’s research activities using our unique technology platform.
About Proteros:
Proteros is a privately held company, which provides services and proprietary technologies to support knowledge-driven drug discovery programs. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ capabilities with its unique technology platform and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan.
About Eisai:
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com/.
Proteros biostructures GmbH
Dr. Thomas Waldmann
Bunsenstrasse 7a
82152 Martinsried
Germany
Phone: +49 89 7007 61 – 0
E-Mail: business@proteros.com
Internet: www.proteros.com
This release was published on openPR.
News-ID: 218204
|
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
Proteros biostructures GmbH
Comments about openPR
We publish our press releases on openPR.de because we like people who are "open" - just like us.
Frank Obels, CEO, INCONET - Informationssysteme, Communication und Netzwerkberatung GmbH
Frank Obels, CEO, INCONET - Informationssysteme, Communication und Netzwerkberatung GmbH